Tadalafil

證據等級: L5

預測適應症: 10 個

Tadalafil: From Original Indication Not Reported to Ambras Type Hypertrichosis Universalis Congenita

One-Sentence Summary

Tadalafil is a phosphodiesterase-5 (PDE5) inhibitor; this dataset does not record its original approved indication or mechanism of action. The TxGNN model predicts it may be effective for Ambras Type Hypertrichosis Universalis Congenita, a rare congenital hair-growth disorder, but this prediction is currently supported by 0 clinical trials and 0 publications.

Quick Overview

Item	Content
Original Indication	Not available in dataset (no marketing licenses or recorded indications)
Predicted New Indication	Ambras Type Hypertrichosis Universalis Congenita
TxGNN Prediction Score	99.98%
Evidence Level	L5
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this dataset. Tadalafil is generally known as a PDE5 inhibitor (general pharmacological knowledge, not sourced from this dataset), used in other markets for conditions such as erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension — none of which are recorded here as its original indication.

There is no known or inferable mechanistic pathway connecting PDE5 inhibition to Ambras type hypertrichosis, a rare genetic disorder linked to chromosomal rearrangement and altered gene regulation. The predicted indication score (99.98%) reflects the TxGNN model’s internal output only and is not corroborated by any independent trial or literature evidence in this pack.

It is also worth noting that the top 10 predictions in this evidence pack collapse into only 5 distinct diseases (each duplicated across two ranks), and the one prediction with literature attached (rank 5, periodontal malformation syndrome) is supported by 20 general periodontitis papers that do not mention tadalafil or PDE5 inhibitors — indicating these are keyword-matched, not drug-specific, references. Taken together, this candidate currently lacks a credible mechanistic or evidentiary basis.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Denmark Market Information

Tadalafil currently holds no marketing authorisation in Denmark (market status: not marketed; 0 licenses on record).

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: This candidate is supported only by a raw TxGNN model score (L5), with no clinical trials, no drug-specific literature, and no plausible mechanistic link between PDE5 inhibition and the predicted disease. A blocking data gap also exists for Danish/EU SmPC warnings and contraindications, which prevents any safety pre-assessment.

To proceed, the following is needed:

Verified mechanism of action (MOA) data for tadalafil
SmPC-sourced warnings, contraindications, and drug interaction data (currently a blocking gap)
Independent clinical or preclinical evidence directly linking tadalafil to Ambras type hypertrichosis (or a mechanistically coherent alternative indication)
Clarification of tadalafil’s actual original indication(s), since this is not recorded in the current dataset
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.